Brief Report: Practicability and safety amphotericin B deoxycholate as continuous infusion in neutropenic patients with hematological malignancies

Leukemia and Lymphoma

Volumn 46, Issue 8, 2005, Pages 1163-1167

  Schulenburg, Axel ^a   Sperr, Wolfgang ^a   Rabitsch, Werner ^a   Knöbl, Paul ^a   Thalhammer, Florian ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Amphotericin B; Continuous infusion; Doses; Hematological malignancies; Side effects

Indexed keywords

ACICLOVIR; AMINOGLYCOSIDE; AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; ANTINEOPLASTIC AGENT; CIPROFLOXACIN; CYCLOSPORIN; DIPYRONE; FLUCONAZOLE; GRANULOCYTE COLONY STIMULATING FACTOR; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; VANCOMYCIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; APLASTIC ANEMIA; ARTICLE; CHILL; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG INFUSION; DRUG SAFETY; FEMALE; FEVER; HEART ARRHYTHMIA; HEMATOLOGIC MALIGNANCY; HUMAN; HYPOKALEMIA; HYPOMAGNESEMIA; MALE; MYCOSIS; NEPHROTOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PYREXIA IDIOPATHICA; THROMBOPHLEBITIS; VOMITING;

ADULT; AGED; AMPHOTERICIN B; ANTIFUNGAL AGENTS; C-REACTIVE PROTEIN; DEOXYCHOLIC ACID; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; FEMALE; FEVER; HEMATOLOGIC NEOPLASMS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MYCOSES; NEUTROPENIA; TREATMENT OUTCOME;

EID: 23144444248     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428190500085214     Document Type: Article

References (19)

1. Brown AE. Overview of fungal infections in cancer patients. Semin Oncol 1990;17(3 Suppl 6):2-5.
2. Young RC, Bennett JE, Vogel CL, Carbone PP, DeVita VT. Aspergillosis. The spectrum of the disease in 98 patients. Medicine (Baltimore) 1970;49:147-173.
3. Bodey G, Bueltmann. B, Duguid W, Gibbs D, Hanak H, Hotchi M, Mall G, Martino P, Meunier F, Milliken S et al. Fungal infections in cancer patients: an international autopsy survey. Ent J Clin Microbiol Infect Dis 1992;11: 99-109.
4. Martino R, Subira, M. Invasive ftingal infections in hematology: new trends. Ann Hematol 2002;81:233-243.
5. Denning DW. Invasive aspergillosis in immunocompromised patients, Curr Opin Infect Dis 1994;7:456-462.
6. EORTC. International Antimicrobial Therapy Cooperative Group. Empiric antifungal therapy in febrile granulocytopenic patients. Am J Med 1989;86(6 Pt 1):668-672.
7. Lyman CA, Walsh TJ. Systemically administered antifungal agents. A review of their clinical pharmacology and therapeutic applications. Drugs 1992;44:9-35.
8. Meyer RD. Current role of therapy with amphotericin B. Clin Infect Dis 1992;14(Suppl. 1):154-160.
9. Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C, Bodensteiner D, Pappas P, Seibel N, Greenberg RN, Dummer S et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999;340:764-771.
10. Eriksson U, Seifert B, Schaffner A. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial. Br Med J 2001;322:579-582.
11. Imhof A, Walter RB, Schaffner A. Continuous infusion of escalated doses of amphotericin B deoxycholate: an open-label observation study. Clin Infect Dis 2003;36:943-951.
12. Speich R, Dutly A, Naef R, Russi EW, Weder W, Boehler A. Tolerability, safety and efficacy of conventional amphotericin B administered by 24-hour infusion to lung transplant recipients. Swiss Med Wkly 2002;132:455-458.
13. Schneemann M, Bachli EB. Continuous infusion of amphotericin B deoxycholate: a cost-effective gold standard for therapy of invasive fungal infections? Clin Infect Dis 2004;38:303-304.
14. Furrer K, Schaffner A, Vavricka SR, Halter J, Imhof A, Schanz U. Nephrotoxicity of cyclosporine A and amphotericin B-deoxycholate as continuous infusion in allogenic stem cell transplantation, Swiss Med Wkly 2002; 132:316-320.
15. Nakase K, Yazald A, Tamaki S, Tanigawa M, Tsuji K, Miyanishi E, Shiku H. Effect of direct infusion of antifungal agent on invasive pulmonary aspergillosis in a patient with acute leukaemia. J Infect Chemother 2002;8:106-108.
16. Ostrosky-Zeichner L, Marr KA, Rex JH, Cohen SH. Amphotericin B: time for a new gold standard. Clin Infect Dis 2003;37:415-425.
17. Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F, Denning DW, Donnelly JP, Edwards JE, Erjavec Z et al. Invasive Fungal Infections Cooperative Group of the European Organization for Research and Treatment of Cancer; Mycoses Study Group of the National Institute of Allergy and Infectious Diseases. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002;34:7-14.
18. Povoa P, Coelho L, Almeida E, Fernandes A, Mealha R, Moreira P, Sabino H. C-reactive protein as a marker of infection in critically ill patients. Clin Microbiol Infect 2005;11:101-108.
19. Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 1982;72:101-111.